Clinical Trial Update: Integrase Inhibitor (MK-0518) Viral Decay [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating viral decay in HIV infections treated with MK-0518 (raltegravir) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Raltegravir (MK-0518) (raltegravir)

Snippet

Sponsor: Canadian Immunodeficiency Research Collaborative | Conditions: HIV Infections | Phase 2 | Status: COMPLETED